Evincis Bio

Evincis Bio was a preclinical-stage biotechnology company focused on developing innovative medical technologies and gene therapies to address therapeutic challenges in urology. A spinout from Johns Hopkins University, the company's lead program, EVI-200, was an SDF-1 mRNA gene therapy delivered via penile injection designed to restore erectile function through endogenous stem cell repair pathways. Evincis Bio utilized nanoparticle carriers to deliver its mRNA therapeutics safely and targetedly. The company was founded in 2020 and received early-stage funding from the Maryland Innovation Initiative (MII) and the National Institutes of Health (NIH) before going out of business in 2023.